We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio In female-to-male transgender patients, ...
Please provide your email address to receive an email when new articles are posted on . Laurenzano, Marinkovic and colleagues conducted a retrospective study analyzing subcutaneous testosterone as ...
The US Food and Drug Administration (FDA) has approved testosterone enanthate (Xyosted, Antares Pharma) subcutaneous injection for testosterone replacement therapy in men diagnosed with conditions ...
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive results from a multi-center phase 2 clinical study evaluating the pharmacokinetic profile of testosterone ...
Antares’ biggest competitive advantage is its Vibex injector platform, which allows rapid subcutaneous self-administration of highly viscous drugs such as testosterone through a fine gauge needle.
(Reuters) - Antares Pharma Inc said its once-weekly testosterone injection met the main goal in an ongoing late-stage study in testosterone-deficient adult males. The U.S. Food and Drug Administration ...
The US Food and Drug Administration (FDA) has declined to approve a new drug application (NDA) for testosterone enanthate (Xyosted, Antares Pharma) in a proprietary autoinjector and has raised two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback